Answers are grounded in this paper and cite their sources.
BAN2401 is a humanized monoclonal antibody that binds with high selectivity to soluble aggregated Aβ (i.e, protofibrils). Study BAN2401-G000-201 is an 18 month, global Phase 2 study in 856 subjects with Early AD, using response adaptive randomization across placebo or 5 active arms. Subjects were required to be amyloid positive on visual read with concurrence by 2 assessors at baseline and were rescanned at 12 and 18 months of treatment. The standard uptake value ratio (SUVr) for a cortical composite versus whole cerebellum was calculated using florbetapir, and visual read was performed for each time point; analyzed using a mixed model repeated measures (MMRM) model and t-tests respectively. Changes from baseline on the primary efficacy measure, ADCOMS, were compared to placebo using an MMRM model. BAN2401 produced dose-dependent effects on amyloid PET, clinical endpoints, and tau CSF biomarkers. Moreover, the clinical effect of BAN2401 on ADCOMS begins at 6 months (p= 0.033) of treatment for the top dose. BAN2401 produced a statistically significant reduction in brain amyloid across all doses tested with the top dose of 10 mg/kg bi-weekly achieving an adjusted mean change from baseline versus placebo of -0.26 (p<0.0001) at 12 months and -0.30 (p<0.0001) at 18 months. Visual read revealed a dose dependent conversion from amyloid positive to amyloid negative in 65% (p<0.0001) and 81% (p<0.0001) of subjects on the top dose at 12 and 18 months, respectively. BAN2401 produced a dose dependent reduction (p=0.011) in clinical decline compared to placebo as measured by ADCOMS, with the top dose significantly reducing decline by 35 % (p=0.027) and 30% (p=0.034) at 12 and 18 months, respectively. BAN2401 demonstrated an acceptable tolerability profile through 18 months of study drug administration. The most common treatment emergent adverse events were infusion-related reactions and Amyloid Related Imaging Abnormalities (ARIA). Infusion related reactions were mostly mild to moderate in severity. Incidence of ARIA-E (edema) was not more than 10% in any of the treatment arms, and less than 15% in patients with APOE4 at the highest dose per the study protocol safety and reporting procedures. BAN2401-G000-201 is the first late-stage study that provides compelling evidence for the amyloid hypothesis. Treatment with BAN2401 produced a dose dependent substantial reduction in brain amyloid plaque at the 10 mg/kg bi-weekly dose, which resulted in the majority of subjects converting to amyloid negative as determined by PET visual read. These results were accompanied by significant reduction in clinical decline compared to placebo as measured by the ADCOMS.
No takes yet. Share an insight, caveat, or question.
Swanson et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: